Camcevi Now Available for Advanced Prostate Cancer Treatment
[ad_1] Home » Specialties » Womens Health Camcevi® (leuprolide mesylate) 42mg injection is now available for the treatment of advanced prostate cancer in adult patients. Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist. The approval was based on data from an open-label, single-arm phase 3 study (ClinicalTrials.gov Identifier:…